{
    "clinical_study": {
        "@rank": "6438", 
        "acronym": "CEPHEUS", 
        "biospec_descr": {
            "textblock": "Whole blood serum"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Centralized Pan-Algerian Survey on the undertreatment of hypercholesterolemia. The purpose\n      of this study is to establish the proportion of patients on lipid-lowering pharmacological\n      treatment reaching the LDL-C goals according to the Third Joint European Task Force\n      guidelines in the survey population."
        }, 
        "brief_title": "Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia", 
        "completion_date": {
            "#text": "March 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hypercholesterolemia", 
            "Cardiovascular Disease", 
            "Hypertension", 
            "Diabetes", 
            "Coronary Heart Disease", 
            "Peripheral Arterial Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases", 
                "Hypercholesterolemia", 
                "Hypertension", 
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Centralised Pan-Algerian Survey on the undertreatment of hypercholesterolemia."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject must provide informed consent and comply with the survey procedures.\n\n          -  Subject is on lipid lowering drug treatment for at least 3 months, with no dose\n             change for a minimum of 6 weeks.\n\n        Exclusion Criteria:\n\n        - Subjects who are unwilling or unable to provide informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "-  Subject must be 19 years of age or older of either gender or race.\n\n          -  Subject must provide informed consent and comply with the survey procedures.\n\n          -  Subject is on lipid lowering drug treatment for at least 3 months, with no dose\n             change for a minimum of 6 weeks"
            }
        }, 
        "enrollment": {
            "#text": "1236", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768403", 
            "org_study_id": "NIS-CDZ-XXX-2012/1"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hypercholesterolemia", 
            "Cardiovascular disease", 
            "Hypertension", 
            "Coronary Heart disease", 
            "Peripheral Arterial disease"
        ], 
        "lastchanged_date": "January 14, 2013", 
        "number_of_groups": "1", 
        "official_title": "Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia", 
        "overall_official": [
            {
                "affiliation": "AstraZeneca", 
                "last_name": "Habib BENNACEUR, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "AstraZeneca", 
                "last_name": "Nawel BOUTEKDJIRET, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Cardiology department /Mustapha Bacha Hospital", 
                "last_name": "Yassin BOUHOUITA-GUERMECH, Professor", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Algeria: Ministry of Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force (TJETF) guidelines.", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768403"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "In the following sub-populations: - Patients with / or not with metabolic syndrome (according to NCEP III definition), - Primary/secondary prevention patients", 
                "measure": "Number and percentage of subjects achieving LDL-C goals according to the TJETF guidelines.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Overall and in the following sub-populations: Patients with/or without metabolic syndrome-Iary/IIary preven", 
                "measure": "Number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III/2004 updated NCEP ATP III and to the 2005 AFSSAPS guidelines", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "For the following sub-populations: Demographic variables, CV risk factors & Lipid-lowering agent class", 
                "measure": "Number and percentage of subjects achieving LDL-C goals according to the : TJETF / NCEP ATP III and 2004 updated NCEP ATP III guidelines.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "The association between achievement of LDL-C goals, according to the Third Joint European Task Force / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables, assessed by multivariate logistic regression models", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}